BR112013020369A8 - peptídeos modificados hidrofóbicos para diagnóstico específico do fígado. - Google Patents

peptídeos modificados hidrofóbicos para diagnóstico específico do fígado.

Info

Publication number
BR112013020369A8
BR112013020369A8 BR112013020369A BR112013020369A BR112013020369A8 BR 112013020369 A8 BR112013020369 A8 BR 112013020369A8 BR 112013020369 A BR112013020369 A BR 112013020369A BR 112013020369 A BR112013020369 A BR 112013020369A BR 112013020369 A8 BR112013020369 A8 BR 112013020369A8
Authority
BR
Brazil
Prior art keywords
modified peptides
hydrophobic modified
specific liver
liver diagnosis
diagnosis
Prior art date
Application number
BR112013020369A
Other languages
English (en)
Other versions
BR112013020369A2 (pt
BR112013020369B1 (pt
Inventor
Mehrle Stefan
Urban Stephan
Mueller Thomas
Haberkorn Uwe
Askoxylakis Vasileios
Mier Walter
Original Assignee
Univ Heidelberg Ruprecht Karls
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Heidelberg Ruprecht Karls filed Critical Univ Heidelberg Ruprecht Karls
Publication of BR112013020369A2 publication Critical patent/BR112013020369A2/pt
Publication of BR112013020369A8 publication Critical patent/BR112013020369A8/pt
Publication of BR112013020369B1 publication Critical patent/BR112013020369B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
BR112013020369-2A 2011-02-10 2012-02-10 Peptídeos modificados hidrofóbicos para diagnóstico específico do fígado BR112013020369B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161441499P 2011-02-10 2011-02-10
US61/441,499 2011-02-10
PCT/EP2012/052343 WO2012107577A1 (en) 2011-02-10 2012-02-10 Hydrophobic modified peptides for liver specific diagnosis

Publications (3)

Publication Number Publication Date
BR112013020369A2 BR112013020369A2 (pt) 2017-05-02
BR112013020369A8 true BR112013020369A8 (pt) 2018-01-09
BR112013020369B1 BR112013020369B1 (pt) 2021-11-03

Family

ID=45581893

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013020369-2A BR112013020369B1 (pt) 2011-02-10 2012-02-10 Peptídeos modificados hidrofóbicos para diagnóstico específico do fígado

Country Status (8)

Country Link
US (1) US10363323B2 (pt)
EP (1) EP2673003B1 (pt)
JP (2) JP6486003B2 (pt)
CN (1) CN103402546B (pt)
BR (1) BR112013020369B1 (pt)
ES (1) ES2708662T3 (pt)
TR (1) TR201901259T4 (pt)
WO (1) WO2012107577A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2673004B1 (en) 2011-02-10 2018-01-24 Ruprecht-Karls-Universität Heidelberg Hydrophobic modified peptides and their use for liver specific targeting
TR201901259T4 (tr) * 2011-02-10 2019-02-21 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Karaciğere özgü tanı için hidrofobik modifiye peptidler.
CA2841249C (en) 2011-07-29 2023-09-26 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
CA3128911C (en) * 2013-01-30 2023-10-17 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
CN105092842B (zh) * 2014-05-15 2017-02-08 中国科学院大连化学物理研究所 一种用于诊断肝癌的联合型代谢标志物及其检测试剂盒
CN105738626B (zh) * 2014-12-12 2017-07-14 中国科学院大连化学物理研究所 一种新的血清代谢物的组合及其作为肝癌诊断标志物的用途
CA3071076A1 (en) * 2017-07-25 2019-01-31 Melanis Co., Ltd. Compositions comprising melanin, and methods of preparing and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE437229T1 (de) 1997-04-30 2009-08-15 Twinstrand Therapeutics Inc Ricin-ähnliche toxine zur therapie von kreb, viraler oder parasitärer infektionen
US7001760B2 (en) 2000-04-20 2006-02-21 Wang-Schick Ryu Hepatitis B virus vectors for gene therapy
US20050074865A1 (en) 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
WO2005084179A2 (en) 2003-12-01 2005-09-15 Immunomedics, Inc. Improved method for preparing conjugates of proteins and chelating agents
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
KR20090114443A (ko) 2007-02-09 2009-11-03 제넨테크, 인크. 항-Ｒｏｂｏ４ 항체 및 그의 용도
CN102015753A (zh) 2008-01-25 2011-04-13 海德堡吕布莱希特-卡尔斯大学 乙肝病毒(HBV)的疏水性修饰的preS-衍生肽及其作为载体将化合物特异性递送到肝脏的用途
WO2009092396A1 (en) * 2008-01-25 2009-07-30 Universitätsklinikum Heidelberg Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors
EP2090584A1 (en) 2008-02-13 2009-08-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Identification of a novel cysteine-rich cell penetrating peptide
US20100233095A1 (en) 2009-01-30 2010-09-16 Adlyfe, Inc. Conformationally dynamic peptides
EP2673004B1 (en) 2011-02-10 2018-01-24 Ruprecht-Karls-Universität Heidelberg Hydrophobic modified peptides and their use for liver specific targeting
TR201901259T4 (tr) 2011-02-10 2019-02-21 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Karaciğere özgü tanı için hidrofobik modifiye peptidler.

Also Published As

Publication number Publication date
BR112013020369A2 (pt) 2017-05-02
BR112013020369B1 (pt) 2021-11-03
WO2012107577A1 (en) 2012-08-16
CN103402546B (zh) 2018-04-13
TR201901259T4 (tr) 2019-02-21
JP2014510050A (ja) 2014-04-24
CN103402546A (zh) 2013-11-20
JP6486003B2 (ja) 2019-03-20
ES2708662T3 (es) 2019-04-10
JP2017081952A (ja) 2017-05-18
US20140356284A1 (en) 2014-12-04
EP2673003B1 (en) 2018-11-07
US10363323B2 (en) 2019-07-30
EP2673003A1 (en) 2013-12-18

Similar Documents

Publication Publication Date Title
CO7020871A2 (es) Anticuerpos anti-il-36r
CR20130677A (es) FORMULACIÓN PARA ANTICUERPO ANTI-a4ß7
CO6811812A2 (es) Anticuerpo anti-b7-h3
BR112013024256A2 (pt) veículo.
CO6801648A2 (es) Formulación para anticuerpo anti-α4β7
CO6970589A2 (es) Ansolvatos de sal de noribogaina
BR112014009498A2 (pt) sistema
BR112013019320A2 (pt) veículo para todos os terrenos.
BR112014004902A2 (pt) peptídeos
CR20140127A (es) Anticuerpo anti-abtcr
BR112013020383A2 (pt) formulações liofilizadas.
CO6801637A2 (es) Formulaciones de anticuerpos
DK2721152T3 (da) Dimere bindingsproteiner baseret på modificerede ubiquitiner
BR112013020369A2 (pt) peptídeos modificados hidrofóbicos para diagnóstico específico do fígado.
DK2782754T3 (da) Svejsbare oblater til PET.
BR112013030897A2 (pt) composição.
FI20116212A (fi) Polypeptidi
ITMI20121619A1 (it) Proiettore.
FR2972076B1 (fr) Actionneur magnetothermique.
CO6841994A2 (es) Anticuerpos
FR2978994B1 (fr) .
DE112012003429A5 (de) Mischereinrichtung
DE112012003438A5 (de) Mischereinrichtung
DE112012002820A5 (de) Hebelsystem
ES2396651B2 (es) Material biosanitario antiulcera.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DESOEFFE

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/02/2012, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2761 DE 05-12-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.